Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
81 Cards in this Set
- Front
- Back
Obligate intracellular parasites that consist of either double or single stranded DNA or RNA enclosed in a protein coat (capsid)
|
viruses
|
|
Some viruses may have a ______ ________ that may contain antigenic glycoproteins like a capsid
|
lipid envelope
|
|
Most viruses contain these which are essential for viral replication inside the host cell-->they hijack host metabolic machinery
|
viral enzymes
|
|
Amantadine, Oseltamivir, Rimantadine, and Zanamivir are all what type of agents
|
anti-influenza agents
|
|
Adefovir, Entecavir, Interferon, Lamivudine, Telbivudine are all what type of agents
|
anti-hepatitis agents
|
|
Acyclovir, Cidofovir, Famiciclovir, Fomivirsen, Foscarnet, Ganciclovir, Penciclovir, Valacyclovir, Valganiciclovir, Vadarabine are all what type of agents
|
anti-herpes virus agents
|
|
what type of herpes includes infections of the mouth, face, skin, esophagus and brain?
|
herpes simplex virus 1 (HSV-1)
|
|
what type of herpes includes infections of the genitals, rectum, hands and meninges?
|
herpes simplex virus 2 (HSV-2)
|
|
This type of herpes virus infects 40% of adults worldwide and most show no symptoms unless immunocompromised or elderly
|
cytomegalovirus (CMV)
|
|
This type of herpes virus is the cause of chicken pox and singles
|
varicella-roster virus (VZV)
|
|
For herpes viruses, what phase of replication do antiviral Rx usually act during?
|
acute phase, NOT latent phase
|
|
This drug is the L-valyl ester of acyclovir and is rapidly converted to acyclovir following oral administration via 1st pass enzymatic hydrolysis
|
Valacyclovir
|
|
Acyclovir is the Rx of choice for ___ ___________ and is most commonly used for genital herpes
|
HSV encephalitis
|
|
This HSV Rx is a GUANOSINE analog that is converted to mono-phosphate form via viral thymidine KINASE
|
acyclovir
|
|
What two forms is acyclovir mono-phosphate converted into and by what?
|
di and tri phosphates by the HOST cell
|
|
This form of acyclovir competes with dGTP as a substrate for viral DNA polymerase and is incorporated into viral DNA causing premature DNA chain termination and also binds IRREVERSIBLY to the DNA polymerase which inactivates the enzyme
|
acyclovir tri-phosphate
|
|
Acyclovir resistance to this type of virus includes:
1. absence or partial production of viral thymidine kinase 2. altered thymidine kinase substrate specificity 3. altered viral DNA polymerase |
herpes simplex virus
|
|
What type of herpes simplex virus is resistant to acyclovir because it lacks a specific viral thymidine kinase
|
cytomegalovirus (CMV)
|
|
MOA for this drug:
converted to a mono-phosphate form via the viral thymidine kinase and is then converted to the di- and tri- phosphate forms by the host cell. the tri-phosphate form competes with dGTP as a substrate for viral DNA polymerase and is incorporated into viral DNA causing premature DNA chain termination *also binds irreversibly to the DNA polymerase inactivating the enzyme |
acyclovir MOA
|
|
These two drugs for HSV are ACYCLIC guanosine nucleoside derivatives
|
famciclovir and penciclovir
|
|
famciclovir is a PRO-DRUG that is metabolized to __________
|
penciclovir
|
|
What is the route of administration for penciclovir
|
topically
|
|
what is the route of administration for famciclovir
|
oral
|
|
HSV1, HSV2, and VZV are the antiviral spectrum for these two drugs
|
penciclovir and famciclovir
|
|
MOA for this drug:
this pro-drug is metabolized to penciclovir, which is then mono-phosphorylated by viral thymidine kinase and cellular enzymes convert it to the triphosphate form which inhibits HSV DNA polymerase |
famciclovir
|
|
This analog of acyclovir has up to 100x greater activity against CMV
*CMV has resistance to acyclovir |
ganciclovir
|
|
MOA for this drug:
Activated through conversion to the triphosphate form by viral and host enzymes and competitively inhibits viral DNA polymerase and is incorporated into DNA, decreasing the rate of chain elongation *much like MOA for acyclovir |
ganciclovir
|
|
Main Rx for cytomegalovirus
|
ganciclovir
|
|
CMV is deficient in thymidine kinase and instead uses protein kinase phosphotransferase, ____
|
UL97
|
|
This drug is approved for treatment of CMV retinitis in AIDS patients
|
cidofovir
|
|
This drug for CMV is a nucleotide analog of CYTOSINE and its phosphorylation is NOT dependent upon viral enzymes
|
cidofovir
|
|
This Rx for CMV has a significant risk for RENAL toxicity and can be administered by IV, intravitreal and topical formulations
|
cidofovir
|
|
This Rx for CMV is an ANTISENSE OLIGONUCLEOTIDE directed against CMV mRNA
|
fomivirsen
|
|
MOA for this drug:
complementary to the mRNA sequence for major immediate-early transcriptional region of CMV and inhibits CMV replication by having the virus bind to the cells |
fomivirsen
|
|
This drug is ACTIVE against CMV strains resistant to ganciclovir, cidofovir and foscarnet
|
fomivirsen
|
|
This Rx for CMV is administered through IV only, and can be used in those who have failed or cannot tolerate other Rx for CMV retinitis
*adverse events: iritis, vitritis, changes in vision |
fomivirsen
|
|
Classification of this type of virus infections:
core proteins (A, B or C), species of origin (avian, swine) and geographic site of isolation |
respiratory influenza strainsq
|
|
What type of influenza is the only form that causes pandemics?
|
influenza A
|
|
What are the three main classes of Rx for respiratory virus infections based on their MOA
|
1. Inhibitors of viral un-coating
2. Inhibitors of neuraminidase 3. Inhibitors of RNA capping and function |
|
These two INFLUENZA A (only) drugs are tricyclic amines
|
amantadine and rimantadine
|
|
___________ is α-methyl derivative of amantadine
|
rimantadine
|
|
Adverse events for these influenza Rx include CNS-related ranging from insomnia → seizures; also embryotoxic and teratogenic in rodents
|
amantadine and rimantadine
|
|
These two Rx for influenza A are 70-90% effective in preventing infection if Rx is begun at time of, or prior to, exposure to the virus
|
amantadine and rimantadine
|
|
MOA for these two influenza drugs:
inhibit VIRAL UN-COATING by blacking M2 (a viral membrane matrix protein that functions as a proton ion channel-required for fusion of viral membrane with cell membrane creating the endosome) |
amantadine and rimantadine
|
|
The acidic environment of the endosome, formed by the fusion of the viral membrane with the cell membrane, is required for what
|
viral uncoating
|
|
By inhibiting the uncoating of the viral RNA within infected host cells, Amantadine and Rimantadine (influenza Rxs) prevent
|
viral replication
|
|
Resistance to amantadine and rimantadine influenza A Rxs develop rapidly in what percentage of patients
|
50%
|
|
MOA for resistance to amantadine and rimantadine:
______ ________ substitution in M2 |
amino acid substitution
|
|
These two influenza Rxs work for influenza A and B and are SIALIC ACID analogs
|
oselamivir and zanamivir
|
|
This influenza Rx is orally delivered pro-drug that is activated via hepatic esterases
|
oseltamivir
|
|
This influenza Rx is delivered directly to the respiratory tract via inhalation with 10-20% of the dose delivered to the lung
|
zanamivir
|
|
These two influenza Rxs are NEURAMINIDASE INHIBITORS for their MOA
|
oseltamivir and zanamivir
|
|
These two influenza drugs competitively and REVERSIBLY interact with the active enzyme site to inhibit its activity causing the viron aggregation at the internal surface of infected cells and decreasing the spread of virus within the respiratory tract
|
oseltamivir and zanamivir
|
|
This influenza virus enzyme is found on the surface of the virus and cleaves SIALIC ACID residues on glycoproteins required for virus replication...the virus attaches to cell surface via hemagglutinin/sialic acid binding during replication
|
neuraminidase enzyme
|
|
Cleavage via this enzyme is essential for release of the virus from infected cells in influenza virus
|
neuraminidase enzyme
|
|
Resistance to these two influenza Rxs is associated with mutations in hemagglutinin and or neuraminidase genes
|
oseltamivir and zanamivir
|
|
This is an Rx for viral respiratory infections and hepatitis
*BROAD SPECTRUM FOR DNA AND RNA VIRUSES |
Ribavirin
|
|
This Rx uses oral admin for hepatitis C virus in combo with interferon and in aerosolized formulation via nebulizer to children and infants with sever RSV bronchiolitis of pneumonia
|
ribavirin
|
|
What is the active form of ribavirin?
|
5’ ribavirin-triphosphate
|
|
What type of anti-virus has viral activities of active drugs that include:
1. Inhibits guanosine triphosphate formation 2. Prevents mRNA capping 3. Blocks RNA-dependent RNA polymerase |
anti-influenza virus
|
|
What are the types of hepatitis viruses?
|
A, B, C and E
|
|
Hepatitis _ and _ are the most common causes of chronic hepatitis, cirrhosis and hepatocellular carcinoma
|
hep B and C
|
|
What type of transmission do HBV and HCV have?
|
blood-borne transmission
*sharing dirty needles, blood transfusion and sexual contact |
|
Current therapies for hep B and C are ________ rather than curative
|
suppressive
|
|
This Rx for hepatitis are host cytokines that exert complex antiviral, immunomodulatory and antiproliferative effects
|
interferons
|
|
What are the three types of interferons
|
α, β, γ
|
|
These are synthesized by host cells in response to various inducer stimuli and cause biochemical changes that result in reduced ability of viruses to infect cells
|
interferons
|
|
Injectable pegylated formulated (subQ and IM-improves t1/2) of IFNα (IFN α-2a and α-2b) are approved for treatment of these two types of hepatitis infections
|
HBV and HCV
|
|
Adverse events of this Rx for hepatitis include:
flu-like symptoms, dose-limiting bone marrow suppression, hypersensitivity and liver toxicity (rare) |
interferon
|
|
MOA for this hepatitis Rx:
Binds to specific receptors and signal via JAK/STAT signaling pathways leading to nuclear translocation of cellular protein complex which binds to genes containing the specific response element→ synthesis > 24 proteins which contribute to viral resistance |
interferon MOA
|
|
Inhibit viral penetration
Inhibit viral gene transcription Inhibit viral protein translation Inhibit viral protein processing Inhibit virus maturation All actions of the MOA of this hepatitis Rx |
interferon
|
|
This hep Rx is specifically for HBV, is well tolerated and has no DDI
*discontinuation of Rx results in severe exacerbation of hepatitis in 25% of patients |
Adefovir dipivoxil
|
|
MOA for this hepatitis Rx:
It is first DE-ESTERIFIED to its pro-drug form and converted to di-phosphate form which is a COMPETITIVE INHIBITOR OF VIRAL DNA POLYMERASE and RT and serves as CHAIN TERMINATOR TO VIRAL DNA SYNTHESIS |
adefovir dipivoxil
|
|
This Rx for hepatitis is a CYTOSINE analog that is activated via phosphorylation by host cell to triphosphate active form
|
lamivudine
|
|
The MOA of this Rx for hepatitis is competitively inhibiting HBV DNA polymerase
*also inhibits HIV reverse transcriptase |
lamivudine
|
|
This hepatitis Rx has enhanced antiviral activity with combo Rx of adefovir or penciclovir against hepatic adenoviruses
|
lamivudine
|
|
Single-nucleotide changes leading to critical amino acid substitutions in a target protein often are sufficient to cause what?
|
antiviral drug resistance
|
|
Current agents inhibit active replication so viral replication may resume following what
|
drug removal
|
|
Most drug-resistant viruses are recovered from __________ patients or those with chronic infections with high viral replicative loads and repeated or prolonged courses of antiviral treatment
|
immunocompromised patients
|
|
Do current antiviral agents eliminate non-replicating or latent virus
|
NO they do not
|
|
Clinical efficacy of antiviral Rx depends on achieving inhibitory concentrations where?
|
at the site of infection, within the infected cells
|